Lexaria Bioscience Secures $4 Million in Capital to Advance 2026 Research and Development Initiatives

Lexaria Bioscience Corp. has closed a $4.0 million registered direct offering, positioning the company to accelerate its research and development initiatives for 2026. The global drug delivery platform innovator sold 2,666,667 shares of common stock at $1.50 per share through a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company issued warrants to purchase an additional 2,666,667 shares with an exercise price of $1.37 per share, immediately exercisable and expiring five years from the registration statement effectiveness date.

The financing provides Lexaria with greater flexibility for its upcoming research and business development strategies. Richard Christopher, CEO of Lexaria Bioscience Corp., emphasized that the funding will enable the company to bring its 2026 plans into focus and execute on R&D initiatives that drive intellectual property development and corporate value. "Most of our study work requires signed contracts prior to ever beginning, therefore we are constantly evaluating our future funding needs," Christopher stated. "In this way, successful financings work towards building shareholder value."

H.C. Wainwright & Co. served as the exclusive placement agent for the offering, which generated approximately $4.0 million in gross proceeds before deducting placement agent fees and other offering expenses. The company plans to allocate the net proceeds toward working capital and other general corporate purposes, supporting the advancement of its DehydraTECH technology platform.

The offering was conducted under a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on January 30, 2025. The prospectus supplement and accompanying prospectus relating to the securities offered in the registered direct offering are available at https://www.sec.gov. The warrants issued in the concurrent private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D, meaning they remain unregistered along with the underlying shares of common stock.

This capital infusion comes at a critical juncture for Lexaria as it seeks to expand its intellectual property portfolio and advance its drug delivery technology. The company's DehydraTECH platform represents a significant innovation in oral drug delivery, with demonstrated capabilities to enhance bio-absorption, reduce side effects, and improve drug delivery across the blood-brain barrier. With 50 patents granted and additional patents pending worldwide, the funding supports Lexaria's position as a leader in pharmaceutical delivery innovation. For additional information about the company's technology and research, visit https://www.lexariabioscience.com.